Hogan Lovells: FDA IND clearance support for Cockayne syndrome gene therapy | Source Library

ArticleGeneral published source

Source type: Article
Access type: Publisher
Publisher: Hogan Lovells
Date: 2026-06-11
Added: 2026-07-05

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

General published source

Publisher type: General media
Bias profile: Elevated

This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 54/100; Weak Support
Clinical outcomes: 54/100; Weak Support
Mechanism: 54/100; Weak Support
Safety: 54/100; Weak Support
Consumer context: 67/100; Context Source
Trial discovery: 54/100; Weak Support

Best used for

Context
Public narrative

Weak for

Clinical claims
Safety conclusions
Regulatory status

Used in Viral Vitalism

Regulatory statusbrief1 reference

First Child Received Experimental Gene Therapy for Cockayne Syndrome

Roles: Regulatory status

Show section-level references

Riaan Research Initiative says 6-year-old Riaan Singh Digeorge became the first patient to receive an experimental AAV9 gene therapy for Cockayne syndrome.

Related studies

No structured study record is currently attached to this source.